Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 Study - Abstract

University of Southern California, Los Angeles, CA.

University of Colorado, Denver, CO; Southwest Oncology Group, Seattle, WA; University of Michigan, Ann Arbor, MI; University of Texas, San Antonio, TX; Wayne State University, Detroit, MI; Cancer and Leukemia Group B/Georgetown University, Washington, DC; Eastern Cooperative Oncology Group/University of Pennsylvania, Philadelphia, PA; and US Oncology/Comprehensive Cancer Centers of Nevada, Las Vegas, NV.

 

 

Men with high-risk features (extraprostatic extension or high Gleason grade) face a high risk of prostate cancer recurrence after radical prostatectomy. Clinical trials of adjuvant systemic therapy for such patients have been limited.

The SWOG (Southwest Oncology Group) S9921 study randomly assigned 983 men with high-risk features at prostatectomy to receive adjuvant therapy with androgen deprivation (ADT) alone or in combination with mitoxantrone chemotherapy. ADT consisted of goserelin and bicalutamide for 2 years.

Although the final primary treatment comparison results are not ready for publication, this article reports results in the ADT-alone control arm with a median follow-up of 4.4 years. For these 481 men, the estimated 5-year biochemical failure-free survival is 92.5% (95% CI, 90 to 95), and 5-year overall survival is 95.9% (95% CI, 93.9 to 97.9).

The results of this trial, taken in context, make a compelling argument for counseling all high-risk patients with prostate cancer about adjuvant ADT. This article discusses the challenges in the design and implementation of clinical trials to take the next step forward in adjuvant therapy for prostate cancer because of the excellent survival achieved with currently available therapies and highlights the need for better molecular markers to personalize care.

Written by:
Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM.   Are you the author?

Reference: J Clin Oncol. 2011 Apr 18. Epub ahead of print.
doi: 10.1200/JCO.2010.32.2776

PubMed Abstract
PMID: 21502546

UroToday.com Prostate Cancer Section

 

 

email news signup